Genetic or pharmacologic inhibition of EGFR ameliorates sepsisinduced AKI

Xuan Xu, Juan Wang, Ruhao Yang, Zheng Dong, Dongshan Zhang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite recent studies have demonstrated that the EGF receptor (EGFR) activation provided a renoprotective role during ischemic and folic acid-induced AKI, the role and regulation mechanism of EGFR in septic AKI remains unclear. Here, gefitinib, a highly selective EGFR inhibitor, abrogated LPS-induced phosphorylation of EGFR, ERK1/2, and STAT3 as well as expression of COX, eNOS, and proinflammatory cytokines in HK-2 cells. In addition, c-Src is an upstream of EGFR signaling pathway and mediates LPSinduced EGFR transactivation. In vivo, either gefitinib or genetic approaches (Wave-2 mutant mice, which have reduced EGFR tyrosine kinase activity) protected against LPS or cecal ligation and puncture (CLP) induced AKI respectively. Interestingly, the beneficial effects of gefitinib or genetic approaches were accompanied by the dephosphorylation of EGFR, ERK1/2, and STAT3, the down regulation of expression of COX, eNOS, macrophage infiltration, proinflammatory cytokines production and the renal cell apoptosis. Furthermore, mRNA array results indicated that gene families involved in cell death, inflammation, proliferation and signal transduction were down regulated in Wave-2 (Wa-2) mice. Take together, these data suggest that EGFR may mediate renal injury by promoting production of inflammatory factors and cell apoptosis. Inhibition of EGFR may have therapeutic potential for AKI during endotoxemia.

Original languageEnglish (US)
Pages (from-to)91577-91592
Number of pages16
JournalOncotarget
Volume8
Issue number53
DOIs
StatePublished - Jan 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Apoptosis
Cytokines
Kidney
Endotoxemia
Punctures
Folic Acid
Protein-Tyrosine Kinases
Transcriptional Activation
Ligation
Signal Transduction
Cell Death
Down-Regulation
Macrophages
Phosphorylation
Inflammation
Messenger RNA
Wounds and Injuries

Keywords

  • CLP
  • EGFR
  • Inflammation

ASJC Scopus subject areas

  • Oncology

Cite this

Genetic or pharmacologic inhibition of EGFR ameliorates sepsisinduced AKI. / Xu, Xuan; Wang, Juan; Yang, Ruhao; Dong, Zheng; Zhang, Dongshan.

In: Oncotarget, Vol. 8, No. 53, 01.01.2017, p. 91577-91592.

Research output: Contribution to journalArticle

Xu, Xuan ; Wang, Juan ; Yang, Ruhao ; Dong, Zheng ; Zhang, Dongshan. / Genetic or pharmacologic inhibition of EGFR ameliorates sepsisinduced AKI. In: Oncotarget. 2017 ; Vol. 8, No. 53. pp. 91577-91592.
@article{0f0b5f77db614a9786bfac6cd3290f20,
title = "Genetic or pharmacologic inhibition of EGFR ameliorates sepsisinduced AKI",
abstract = "Despite recent studies have demonstrated that the EGF receptor (EGFR) activation provided a renoprotective role during ischemic and folic acid-induced AKI, the role and regulation mechanism of EGFR in septic AKI remains unclear. Here, gefitinib, a highly selective EGFR inhibitor, abrogated LPS-induced phosphorylation of EGFR, ERK1/2, and STAT3 as well as expression of COX, eNOS, and proinflammatory cytokines in HK-2 cells. In addition, c-Src is an upstream of EGFR signaling pathway and mediates LPSinduced EGFR transactivation. In vivo, either gefitinib or genetic approaches (Wave-2 mutant mice, which have reduced EGFR tyrosine kinase activity) protected against LPS or cecal ligation and puncture (CLP) induced AKI respectively. Interestingly, the beneficial effects of gefitinib or genetic approaches were accompanied by the dephosphorylation of EGFR, ERK1/2, and STAT3, the down regulation of expression of COX, eNOS, macrophage infiltration, proinflammatory cytokines production and the renal cell apoptosis. Furthermore, mRNA array results indicated that gene families involved in cell death, inflammation, proliferation and signal transduction were down regulated in Wave-2 (Wa-2) mice. Take together, these data suggest that EGFR may mediate renal injury by promoting production of inflammatory factors and cell apoptosis. Inhibition of EGFR may have therapeutic potential for AKI during endotoxemia.",
keywords = "CLP, EGFR, Inflammation",
author = "Xuan Xu and Juan Wang and Ruhao Yang and Zheng Dong and Dongshan Zhang",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21244",
language = "English (US)",
volume = "8",
pages = "91577--91592",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "53",

}

TY - JOUR

T1 - Genetic or pharmacologic inhibition of EGFR ameliorates sepsisinduced AKI

AU - Xu, Xuan

AU - Wang, Juan

AU - Yang, Ruhao

AU - Dong, Zheng

AU - Zhang, Dongshan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Despite recent studies have demonstrated that the EGF receptor (EGFR) activation provided a renoprotective role during ischemic and folic acid-induced AKI, the role and regulation mechanism of EGFR in septic AKI remains unclear. Here, gefitinib, a highly selective EGFR inhibitor, abrogated LPS-induced phosphorylation of EGFR, ERK1/2, and STAT3 as well as expression of COX, eNOS, and proinflammatory cytokines in HK-2 cells. In addition, c-Src is an upstream of EGFR signaling pathway and mediates LPSinduced EGFR transactivation. In vivo, either gefitinib or genetic approaches (Wave-2 mutant mice, which have reduced EGFR tyrosine kinase activity) protected against LPS or cecal ligation and puncture (CLP) induced AKI respectively. Interestingly, the beneficial effects of gefitinib or genetic approaches were accompanied by the dephosphorylation of EGFR, ERK1/2, and STAT3, the down regulation of expression of COX, eNOS, macrophage infiltration, proinflammatory cytokines production and the renal cell apoptosis. Furthermore, mRNA array results indicated that gene families involved in cell death, inflammation, proliferation and signal transduction were down regulated in Wave-2 (Wa-2) mice. Take together, these data suggest that EGFR may mediate renal injury by promoting production of inflammatory factors and cell apoptosis. Inhibition of EGFR may have therapeutic potential for AKI during endotoxemia.

AB - Despite recent studies have demonstrated that the EGF receptor (EGFR) activation provided a renoprotective role during ischemic and folic acid-induced AKI, the role and regulation mechanism of EGFR in septic AKI remains unclear. Here, gefitinib, a highly selective EGFR inhibitor, abrogated LPS-induced phosphorylation of EGFR, ERK1/2, and STAT3 as well as expression of COX, eNOS, and proinflammatory cytokines in HK-2 cells. In addition, c-Src is an upstream of EGFR signaling pathway and mediates LPSinduced EGFR transactivation. In vivo, either gefitinib or genetic approaches (Wave-2 mutant mice, which have reduced EGFR tyrosine kinase activity) protected against LPS or cecal ligation and puncture (CLP) induced AKI respectively. Interestingly, the beneficial effects of gefitinib or genetic approaches were accompanied by the dephosphorylation of EGFR, ERK1/2, and STAT3, the down regulation of expression of COX, eNOS, macrophage infiltration, proinflammatory cytokines production and the renal cell apoptosis. Furthermore, mRNA array results indicated that gene families involved in cell death, inflammation, proliferation and signal transduction were down regulated in Wave-2 (Wa-2) mice. Take together, these data suggest that EGFR may mediate renal injury by promoting production of inflammatory factors and cell apoptosis. Inhibition of EGFR may have therapeutic potential for AKI during endotoxemia.

KW - CLP

KW - EGFR

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85032653512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032653512&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21244

DO - 10.18632/oncotarget.21244

M3 - Article

AN - SCOPUS:85032653512

VL - 8

SP - 91577

EP - 91592

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 53

ER -